Daina Graybosch
Stock Analyst at Leerink Partners
(1.28)
# 3,690
Out of 5,116 analysts
98
Total ratings
41.18%
Success rate
-7.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $1.04 | +92.31% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.70 | +17.65% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.67 | +200.62% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.85 | +278.38% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $18.38 | -34.71% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $106.45 | +11.79% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.25 | +280.95% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $66.00 | -40.91% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $43.94 | +2.41% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.01 | +890.10% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $23.12 | +64.36% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.34 | +84.33% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $95.03 | +135.72% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.82 | +1,548.35% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.66 | +2,474.20% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.54 | +484.42% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $1.04
Upside: +92.31%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.70
Upside: +17.65%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.67
Upside: +200.62%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.85
Upside: +278.38%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $18.38
Upside: -34.71%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $106.45
Upside: +11.79%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.25
Upside: +280.95%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $66.00
Upside: -40.91%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $43.94
Upside: +2.41%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.01
Upside: +890.10%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $23.12
Upside: +64.36%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.34
Upside: +84.33%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $95.03
Upside: +135.72%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.82
Upside: +1,548.35%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.66
Upside: +2,474.20%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.54
Upside: +484.42%